Population based studies

基于人群的研究

• 批准号: 8157697
• 负责人: Carl Ola Landgren
• 金额: $ 9.73万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8157697
• 关键词: Affect; Biological Assay; Chronic Lymphocytic Leukemia; Clinical; Disease; Early treatment; Future; Goals; Individual; Intervention; Intervention Studies; Knowledge; Modeling; Monoclonal gammopathy of uncertain significance; Multiple Myeloma; Patients; Preclinical Drug Evaluation; Research; Sampling; Testing; disease mechanisms study; improved; mouse model; population based; programs; prospective; tumor progression

Using population-based approaches and biomarker assays on stored samples (in exisiting large biobanks) allows my research to move forward more quickly. I can use these strategies in parallel with my clinical program - to test important questions and to identify candidate assays and targets. In parallel, I develop prospective patient studies for individuals affected with myeloma precursor disease, early intervention studies (MGUS and smoldering myeloma), and targeted myeloma treatment studies. By taking these parallel approaches, and by constantly developing and improving our concepts, I bevieve that we will be able to delay progression and ultimately cure patients from myeloma in the future. Currently, we are developing a myeloma mouse model. The aim of this effort is to develop a model to study mechanisms of disease, and to allow us to do drug screening.

使用基于人群的方法和生物标志物分析存储的样本（在验证大型生物库）使我的研究能够更快地向前推进。我可以将这些策略与我的临床计划并行使用-以测试重要问题并确定候选检测方法和靶标。与此同时，我为患有骨髓瘤前驱疾病的个体开展了前瞻性患者研究，早期干预研究（MGUS和郁积型骨髓瘤）和靶向骨髓瘤治疗研究。 通过采取这些平行的方法，并不断发展和改进我们的概念，我相信我们将能够延迟进展，并最终治愈骨髓瘤患者。 目前，我们正在开发骨髓瘤小鼠模型。这项工作的目的是开发一个模型来研究疾病的机制，并允许我们进行药物筛选。